To include your compound in the COVID-19 Resource Center, submit it here.

Building momentum

Why investors flocked to cell therapy company Avrobio’s $60M series B round

Avrobio Inc. parlayed positive clinical data and an aggressive in-licensing strategy into a $60 million series B round that will fund early clinical development of three long-acting lysosomal storage disease candidates.

Cormorant Asset Management and Surveyor Capital led the

Read the full 387 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE